» Articles » PMID: 14992415

Resistance Issues and Community-acquired Respiratory Infections

Overview
Specialty Public Health
Date 2004 Mar 3
PMID 14992415
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Antimicrobial resistance, associated with both excessive and inappropriate use of antimicrobial agents, is a global problem. It is a particular problem in the management of community-acquired respiratory infections, which most often result in the use of antimicrobial therapy. Infections caused by resistant and multiresistant pathogens may also result in high hospitalization rates, long lengths of stay, severe illness, and high mortality, all of which have a great impact on health care costs. The Tracking Resistance in the United States Today (TRUST) Program, the largest longitudinal continuous-surveillance program of its kind, has been conducted every year since 1996 and tracks consecutive respiratory seasons on a year-to-year basis to monitor resistance patterns of respiratory pathogens. This article discusses some of the findings of the TRUST Program, particularly trends in Streptococcus pneumoniae resistance.

Citing Articles

Clinical applications of azithromycin microspheres in respiratory tract infections.

Blasi F, Aliberti S, Tarsia P Int J Nanomedicine. 2008; 2(4):551-9.

PMID: 18203423 PMC: 2676803.


Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Swainston Harrison T, Keam S Drugs. 2007; 67(5):773-92.

PMID: 17385947 DOI: 10.2165/00003495-200767050-00010.


Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x.

Davies T, Shang W, Bush K Antimicrob Agents Chemother. 2006; 50(7):2530-2.

PMID: 16801437 PMC: 1489808. DOI: 10.1128/AAC.00238-06.


Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000.

Davies T, Bush K, Sahm D, Evangelista A Antimicrob Agents Chemother. 2005; 49(7):3031-3.

PMID: 15980393 PMC: 1168632. DOI: 10.1128/AAC.49.7.3031-3033.2005.


Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.

Korzheva N, Davies T, Goldschmidt R Antimicrob Agents Chemother. 2005; 49(6):2479-86.

PMID: 15917550 PMC: 1140505. DOI: 10.1128/AAC.49.6.2479-2486.2005.